Inherent Biosciences utilizes AI to analyze epigenetic profiles in sperm, providing precise insights into fertility outcomes and reproductive health. The company addresses the challenges of trial and error medicine by offering personalized fertility testing and treatment plans to help couples achieve pregnancy more effectively.
Funding
$9.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current fertility testing methods often rely on trial and error, leading to prolonged time to pregnancy and increased emotional and financial burden for couples. Existing diagnostic approaches may lack the precision needed to identify underlying issues affecting sperm quality and reproductive health.
Solution
Inherent Biosciences leverages artificial intelligence to analyze epigenetic profiles in sperm, providing a more precise assessment of male fertility potential. Their technology identifies observable patterns in epigenetic modifiers, which correlate with important biological functions of sperm and can predict fertility outcomes. By analyzing these epigenetic markers, Inherent Biosciences aims to personalize fertility testing and treatment plans, helping couples achieve pregnancy more effectively and efficiently. The company's SpermQT product seeks to raise the standard of care in reproductive health by offering more personalized and effective treatment plans.
Target Audience
The primary target audience includes couples experiencing infertility, fertility clinics, and reproductive health specialists seeking advanced diagnostic tools for male fertility assessment.
Features
- AI-driven analysis of sperm epigenetic profiles
- Identification of epigenetic markers indicative of fertility outcomes
- Prediction of sperm biological functions based on epigenetic patterns
- Personalized fertility testing and treatment plans